Your browser doesn't support javascript.
Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis.
Berardicurti, Onorina; Ruscitti, Piero; Ursini, Francesco; D'Andrea, Settimio; Ciaffi, Jacopo; Meliconi, Riccardo; Iagnocco, Annamaria; Cipriani, Paola; Giacomelli, Roberto.
  • Berardicurti O; Department of Biotechnological and Applied Clinical Sciences, Rheumatology Unit, University of L'Aquila, Italy. berardicurtio@libero.it.
  • Ruscitti P; Department of Biotechnological and Applied Clinical Sciences, Rheumatology Unit, University of L'Aquila, Italy.
  • Ursini F; IRRCS Istituto Ortopedico Rizzoli, Bologna, and Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy.
  • D'Andrea S; Department of Life, Health and Environment Sciences, Andrology Unit, University of L'Aquila, Italy.
  • Ciaffi J; IRRCS Istituto Ortopedico Rizzoli, Bologna, Italy.
  • Meliconi R; IRRCS Istituto Ortopedico Rizzoli, Bologna, and Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy.
  • Iagnocco A; Dipartimento Scienze Cliniche e Biologiche, Università degli Studi di Torino, Italy.
  • Cipriani P; Department of Biotechnological and Applied Clinical Sciences, Rheumatology Unit, University of L'Aquila, Italy.
  • Giacomelli R; Allergology, Immunology, Rheumatology Unit, Department of Medicine, Università Campus Bio-Medico di Roma, Italy.
Clin Exp Rheumatol ; 38(6): 1247-1254, 2020.
Article in English | MEDLINE | ID: covidwho-958707
ABSTRACT

OBJECTIVES:

People who are exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could develop a potentially fatal disease with lung involvement and severe cytokine storm syndrome (CSS) - coronavirus disease 2019 (hereafter, COVID-19). Tocilizumab (TCZ) was administered to these subjects, despite the lack of randomised clinical trial data. Hence, summarising data on the mortality rate and related risks factors may help physicians to correctly administer TCZ.

METHODS:

We performed a systematic review and meta-analysis on mortality rate in TCZ- treated patients with COVID-19 according to the PRISMA guidelines. The pooled mortality rate in TCZ-treated persons was calculated and meta-regressions were done to investigate associated factors.

RESULTS:

We included 22 studies and 1520 TCZ-treated patients (mean age 61 years, 95% CI 59-64; male 71%, 95% CI 64-78%). The mortality estimated pooled prevalence was 19% (95% CI 13-25, I2=100%, p<0.00001) and improvement estimated pooled prevalence was 71% (95% CI 62-81). Factors associated with the mortality are the number of patients in intensive care unit, the number of patients requiring invasive ventilation and the sera C-reactive protein value before TCZ administration. We observed a reduction in the odds of mortality in TCZ-treated patients when compared to those treated with other therapies (OR=0.47, 95% CI 0.22-0.98, p=0.004).

CONCLUSIONS:

This study showed that the mortality pooled prevalence in TCZ-treated patients is lower than the overall mortality reported in patients with severe COVID-19.
Subject(s)
Search on Google
Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Betacoronavirus / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Limits: Humans / Male / Middle aged Language: English Journal: Clin Exp Rheumatol Year: 2020 Document Type: Article Affiliation country: Italy

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Betacoronavirus / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Limits: Humans / Male / Middle aged Language: English Journal: Clin Exp Rheumatol Year: 2020 Document Type: Article Affiliation country: Italy